Healio

First patient dosed in Melt’s phase 3 program of needle- and opioid-free cataract sedation

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MELT-300 is a combination of midazolam and ketamine ...
Healio

Virtual reality can make needles less scary

A health care tool for an overlooked public health problemFear of needles is one of health care’s most common, and most ...
Business Wire

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an ...
Business Wire

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first ...
The New England Journal of Medicine

Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis

In a multicenter, double-blind trial, we randomly assigned mechanically ventilated adults with sepsis to receive dexmedetomidine (0.2 to 1.5 μg per kilogram of body weight per hour) or propofol (5 to ...